Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06037681 · ClinicalTrials.gov registry record

Cannabis Use and Outcomes in Black and White Patients With Cancer

A clinical trial of Cancer, sponsored by State University of New York at Buffalo.

Recruiting
Registry status
600
Enrollment target
3
Study locations

NCT06037681 is a study of Cancer that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 600 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06037681, a study of Cancer, is actively recruiting participants, sponsored by State University of New York at Buffalo.

RECRUITING
Registry status
600 participants
Enrollment target
3
Study locations

Study Summary

The goal of the observational study is to learn how black and white patients with solid tumor cancer use cannabis, opioids and tobacco. The investigators are using momentary ecological assessment through a smart phone app and surveys to assess patient-reported pain and other symptoms as to inform clinical practice and guidelines for underrepresented populations.

Conditions Studied

Study Locations (3)

Pennsylvania

  • Thomas Jefferson University - Philadelphia
  • University of Pennsylvania - Philadelphia

New York

  • University at Buffalo - Buffalo

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2023-03-30
Est. Completion 2027-03-30

What the Registry Record Tells You About NCT06037681

The ClinicalTrials.gov registry entry for NCT06037681 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (83% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT06037681 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, New York.

Frequently Asked Questions

What is clinical trial NCT06037681 about?

NCT06037681 is a clinical study titled "Cannabis Use and Outcomes in Black and White Patients With Cancer". The goal of the observational study is to learn how black and white patients with solid tumor cancer use cannabis, opioids and tobacco. The investigators are using momentary ecological assessment through a smart phone app and surveys to assess patient-reported pain and other symptoms as to inform cl...

What is the current status of trial NCT06037681?

This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2023-03-30. Estimated completion is 2027-03-30.

What conditions does trial NCT06037681 study?

This clinical trial studies the following conditions: Cancer.

Who is sponsoring clinical trial NCT06037681?

This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06037681 being conducted?

This trial has 3 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.